News Search Results
Nov 17, 2025, 06:30 ET Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Nov 16, 2025, 21:29 ET Akeso's Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China
options for Alzheimer's patients. CNS disorders have long posed significant therapeutic challenges on a global scale. Akeso, with its deep expertise in bispecific antibody development, is at the forefront of creating novel therapies to address critical unmet clinical needs in CNS diseases.
More news about: Akeso, Inc.
Nov 15, 2025, 11:00 ET BrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at the 2025 Society for Neuroscience Annual Meeting
system of endothelial cells, astrocytes, and pericytes accurately replicates barrier integrity and permeability, providing a quantitative platform for CNS drug transport and safety studies. Poster presentation: Nov. 15th at 1:00 p.m. at location #369.09. Another study details an accelerated
More news about: BrainXell, Inc
Nov 14, 2025, 16:05 ET Cohen & Steers Announces Changes to Realty Indexes
NEW YORK, Nov. 14, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as
More news about: Cohen & Steers, Inc.
Nov 14, 2025, 16:01 ET Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Nov 14, 2025, 09:26 ET Curis to Present at Upcoming 30th Annual SNO Meeting
orally available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the
More news about: Curis, Inc.
Nov 13, 2025, 08:33 ET CNS Summit 2025 Honors Robert Langer with Leadership Award for Transformative Impact in Life Sciences Innovation
Nov. 13, 2025 /PRNewswire/ -- The Leadership Council of CNS Summit (Collaborating for Novel Solutions) is proud to announce that Robert S. Langer, Institute Professor at MIT, has been selected as recipient of the 2025 CNS Summit Leadership Award in recognition of his enduring contributions
More news about: CNS Summit
Nov 13, 2025, 08:00 ET Cohen & Steers Promotes Daniel Noonan to Head of Global Distribution
NEW YORK, Nov. 13, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that Daniel Noonan, Executive Vice President and Head of Global Wealth, has been promoted to Head of Global Distribution. Mr. Noonan
More news about: Cohen & Steers, Inc.
Nov 13, 2025, 08:00 ET LISCure Expands Global Partnerships for BBB Shuttle Platform 'ExoPN-101'; Signs Fourth MTA with Leading Pharma Partner
therapeutics through advanced platform innovation. The company's pipeline includes ExoPN-101, a proprietary BBB shuttle platform for central nervous system (CNS) drug delivery, and LB-P8, a Phase 2 therapeutic candidate for Primary Sclerosing Cholangitis (PSC). LISCure aims to advance cutting-edge science into
More news about: LISCure BioSciences
Nov 12, 2025, 08:30 ET Corundum Neuroscience Invests in NextSense to Support Commercialization of Smartbuds
Corundum Neuroscience (CNS), the neuroscience venture builder and fund announced today they have participated in a Series A funding round for
More news about: Corundum Neuroscience
Nov 11, 2025, 07:45 ET Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
preclinical research evaluating Modeyso™ (dordaviprone), as well as new preclinical data featuring JZP3507 (formerly ONC206) in central nervous system (CNS) tumors, reflecting Jazz's growing impact and innovation in neuro-oncology. Key presentations include:
More news about: Jazz Pharmaceuticals plc
Nov 10, 2025, 16:22 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for October 2025
NEW YORK, Nov. 10, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $90.6 billion as of October 31, 2025, a decrease of $312 million from assets under management
More news about: Cohen & Steers, Inc.
Nov 10, 2025, 09:00 ET NEURELIS TO PARTICIPATE IN SOFIE'S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT
narrow-angle glaucoma Central Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Nov 10, 2025, 08:00 ET Servier's Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma
Astrocytoma, IDH-mutant (CNS WHO grades 2-4) Oligodendroglioma, IDH-mutant and1p19q-codeleted (CNS WHO grades 2-3) Glioblastoma, IDH-wildtype (CNS WHO grade 4)
More news about: Servier Pharmaceuticals
Nov 07, 2025, 08:58 ET Resonant Wins BioTech Breakthrough Awards' "DNA Sequencing Innovation Of The Year"
Resonant turns next-generation sequencing into a practical, blood-based view of active CNS injury, revealing meaningful biology when intervention has the greatest chance of success. A simple blood draw delivers a scalable, CNS-resolved measure of active neurodegeneration that sets a new standard for how sequencing
More news about: Resonant
Nov 06, 2025, 16:00 ET Curis Provides Third Quarter 2025 Business Update
NHL/CLL Curis will report clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19-23:
More news about: Curis, Inc.
Nov 06, 2025, 12:12 ET A Corero Network Security aproveita os resultados do terceiro trimestre com grandes conquistas no quarto trimestre e avanços em seus produtos
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), líder reconhecida em proteção contra DDoS e campeã de disponibilidade de serviços adaptáveis e em tempo real, relatou hoje uma aceleração
More news about: Corero Network Security
Nov 06, 2025, 12:10 ET Corero Network Security se apoya en la ejecución del tercer trimestre con importantes logros y avances de productos en el cuarto trimestre
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), líder reconocida en protección contra ataques distribuidos de denegación de servicio (DDoS, por sus siglas en inglés) y defensora de
More news about: Corero Network Security
Nov 06, 2025, 09:00 ET NEURELIS TO PRESENT STUDY OF NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT SYMPTOMATIC CEREBRAL CAVERNOUS MALFORMATIONS (CCM), AT ANNUAL CCM MEETING
narrow-angle glaucoma Central Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Nov 06, 2025, 07:00 ET NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
expected impact of his expertise on the Company's research and development programs, and the potential advancement of NewcelX's combined cell therapy and CNS drug development platforms following the merger of Kadimastem and NLS Pharmaceutics and its ability to deliver meaningful therapeutic advances for patients
More news about: NewcelX Ltd.
Nov 05, 2025, 12:01 ET Connected Nation curates AI training and literacy resources to ensure new learners are skilled for the future
Empower AI Learners: Train at least 50,000 K–12 students in AI literacy and application skills through CN's national digital empowerment programs, with a focus on rural and underserved communities. Advance
More news about: Connected Nation
Nov 05, 2025, 08:34 ET CNS Summit releases annual Digital Innovation Index
BOSTON, Nov. 5, 2025 /PRNewswire/ -- The CNS Summit Digital Innovation Index, created in partnership with IDEA Pharma, a division of SAI Med Partners, was unveiled during the CNS Summit annual meeting on November 4. The Index continues to assess and rank biopharma
More news about: CNS Summit
Nov 05, 2025, 03:00 ET Corero Network Security Builds on Q3 Execution with Major Q4 Wins and Product Breakthroughs
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today reported accelerating global
More news about: Corero Network Security
Nov 05, 2025, 03:00 ET Corero Network Security Builds on Q3 Execution with Major Q4 Wins and Product Breakthroughs
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today reported accelerating global
More news about: Corero Network Security
Nov 04, 2025, 17:12 ET Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.